Developer docs
API playgroundTry for free, no card

Search company profiles

General Inception

Full company profile

uuid0007onz

Namestring
General Inception
Legal namestring
General Inception
Company typeenum
Private
Founded yearint
2020
Descriptiontext

General Inception is a deep tech venture studio founded in 2020 and headquartered in Palo Alto, California, that operates as a business co-founder for science-based companies. The studio partners with technical and scientific founders across engineered biology, life science tools and diagnostics, and therapeutics, guiding ventures from idea through seed investment and beyond via an "Igniter" model that supplies legal, financial, business strategy, and operations support alongside access to talent, customers, and institutional capital. As of recent disclosures, the studio maintains a portfolio of more than 13 biotech companies and operates with a team of 11-50 employees plus more than 20 Executives-in-Residence, with regional teams in France, Belgium, the Netherlands, and the United Kingdom through the Igniter Europe program launched in April 2024.

The studio's technology stack is anchored by two AI- and computational-driven platforms acquired or allied over 2023-2024. Enable Medicine (acquired December 2024) provides the Enable Atlas, a multimodal biological dataset indexed across billions of cells and thousands of patient data sets, and applies generative AI to search disease maps for novel drug targets and indications. Pharmacelera, under a 2023 strategic alliance, contributes a quantum mechanics and AI drug discovery platform that has completed more than 100 projects with repeat business from three big pharma clients. The studio's broader portfolio includes Resolve M Therapeutics (pro-resolution immunology, created with Johnson & Johnson Innovation – JJDC), Ennovate Pharma (autoimmune and inflammatory therapeutics), SonoNeu (sonogenetics, with up to $41.3M in ARPA-H funding), Biocellis (bioluminescence diagnostics with Institut Pasteur), Surf Therapeutics (ultrasound neuromodulation), and Planet Smart (biodegradable superabsorbent polymers).

General Inception's revenue model combines portfolio company equity appreciation with services revenue. Fractional services including Transformation Services, Fractional Finance, and Lab Services (GIL'S) originated as internal portfolio support and have expanded to external clients, while investors back the studio directly; named backers include Genoa Ventures, Hughes Ventures, Northpond Ventures, OMX Ventures, Paladin Capital Group, and Vertical Venture Partners. Pricing is not publicly disclosed and the studio does not report standalone revenue figures, with returns materially tied to portfolio company outcomes rather than product sales.

Short descriptiontext

General Inception is a deep tech venture studio that co-founds biotech companies with scientific founders, operating a portfolio of 13+ companies across engineered biology, life sciences tools, diagnostics, and therapeutics, enhanced by AI and quantum-mechanics drug discovery platforms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture studio services, biotech company creation, deep tech incubation, fractional executive services, AI drug discovery
Industry1 code
PRIMARYFSANAAAH
Venture Studios / Company Builders
NAICS code4 codes
  • Portfolio Management and Investment Advice523940
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Other Scientific and Technical Consulting Services54169
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Management Consulting Services8742
  • Investment Advice6282
Product category
Venture Studio / Biotech Incubation Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Portfolio Company Returns
TypeLicensing Royalties
Description

General Inception operates as a venture studio that creates and scales biotech companies. Revenue is generated through successful portfolio company exits and equity appreciation.

generalinception.com
2Services Revenue
TypeProfessional Services
Description

Fractional services including Transformation Services, Fractional Finance, and Lab Services are offered to portfolio companies and external clients. Services began as internal support but expanded to serve external customers.

generalinception.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

General Inception operates as a Deep Tech Venture Studio that co-founds science-based companies with extraordinary technical founders, providing business co-founding services that span talent sourcing, customer introductions, and funding access from idea through seed investment and beyond. Complementing venture creation, GI sells discrete professional services — Transformation Services (fractional executive leadership for turnarounds and growth), Fractional Finance (CFO-level finance and accounting support), and Lab Services / GIL'S (R&D operations across fibrosis, oncology, inflammation, and autoimmune disease) — to portfolio companies and external clients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Successfully created Ennovate Pharma with validated targets for autoimmune disease non-responders
+3 more records
Product overview1 text field

General Inception is a Deep Tech Venture Studio that operates as a business co-founder, partnering with scientific founders to build biotech companies. Rather than a single product, GI offers a portfolio of venture-building services (Transformation Services, Fractional Finance, Lab Services/GIL'S, Program Development Manager) and the Igniter Europe initiative for European company formation. GI's ecosystem includes 13+ portfolio companies spanning engineered biology, life science tools & diagnostics, and therapeutics, with core AI capabilities through the Enable Medicine acquisition enabling AI-led generative biological search for drug discovery.

Product and service1 record
1Transformation Services
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

Salk Institute scientist Sreekanth Chalasani leads an ARPA-H project with up to $41.3M funding. Collaborating institutions include Scripps Research, Duke University, MIT, UC San Diego, California Medical Innovations Institute, and SonoNeu (a General Inception spinout).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-22
Description

Resolve M Therapeutics was created through a strategic collaboration between Johnson & Johnson Innovation – JJDC and General Inception, leveraging insights from Professor Nir Hacohen's lab at the Broad Institute.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-18
Description

Biocellis announced equity partnership with General Inception and strategic collaboration with Institut Pasteur to accelerate bioluminescence-based diagnostics development and expand commercial reach of LuLISA technology.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-12-12
Description

General Inception acquired Enable Medicine and announced an equity and strategic partnership. The partnership provides GI greater access to Enable's biological data platform while Enable benefits from GI's drug development expertise and biotech ecosystem. The two companies first collaborated in 2023 to establish Ennovate Pharma.

5Professor James Zou
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-12-12
Description

AI pioneer in life sciences and medicine; member of Enable Medicine's Scientific Advisory Board. Provided commentary on the transformative potential of Enable's biological data indexing and interrogation technology.

generalinception.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-12
Description

Joint venture between General Inception and Enable Medicine established in 2023. Develops precision therapeutics for autoimmune and inflammatory diseases by leveraging biological atlases to identify and understand patient non-response to standard-of-care treatments. After 18 months, addressing refractory and non-responder populations with several validated targets.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-12
Description

Research collaboration with Professor Nir Hacohen's lab at the Broad Institute provided foundational science for Resolve M Therapeutics' pro-resolution platform for inflammatory diseases.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-01-01
Description

General Inception established 2023 strategic alliance with Pharmacelera, where Pharmacelera became GI's strategic partner for AI-based drug discovery. GI's Chief Scientific Officer sits on Pharmacelera's Board of Directors. Pharmacelera has contributed to strengthening IP for several GI portfolio companies.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

IndieBio is a biotech accelerator that funds and incubates early-stage science startups, with programs in both San Francisco and New York. It is comparable to General Inception's deep-tech focus and venture creation model, though structured more as an accelerator than a long-term builder.

TypeBroad incumbent
Description

Evotec is a global drug discovery and development company with a venture-building arm (e.g., Evotec's BRIDGE initiative) that co-creates biotech companies. As a much larger public company with broader CRO offerings, Evotec is an incumbent comparable to General Inception's biotech venture building activities.

TypeBroad incumbent
Description

BridgeBio operates multiple subsidiary biotechs targeting genetic diseases through a portfolio model. Its broader scope and public market status make it a comparable incumbent, with similar strategic use of subsidiary structures and a focus on advancing multiple programs in parallel.

TypeBroad incumbent
Description

Recursion is an AI-driven drug discovery company that combines proprietary data platforms with a portfolio approach to therapeutic development. Its use of generative AI and large biological datasets to accelerate drug discovery is comparable to General Inception's Enable Medicine platform strategy.

TypeDirect peer
Description

Flagship Pioneering is the largest and most established biotech venture studio, originating companies like Moderna. It is the closest analog to General Inception's model of creating and incubating multiple biotech ventures from scientific founders, with comparable portfolio scale and pharma partnership intensity.

TypeDirect peer
Description

MBC Biolabs operates shared lab facilities and incubator programs for biotech startups in the San Francisco Bay Area. It represents a comparable biotech venture creation model focused on early-stage company formation with shared infrastructure — directly analogous to GIL'S Lab Services offering within General Inception.

TypeBroad incumbent
Description

Roivant builds and operates multiple biotech subsidiaries (Vants) across therapeutic areas, using a hub-and-spoke model similar to GI's portfolio structure. While publicly traded and much larger, Roivant's approach to creating focused subsidiaries from scientific platforms is highly comparable to General Inception's portfolio strategy.

8Petri
TypeDirect peer
Description

Petri is a biotech venture studio that partners with scientists to launch new companies. It shares General Inception's focus on company creation at the intersection of biology and technology, though Petri operates at smaller scale and earlier stage.

TypeDirect peer
Description

Apollo Therapeutics is a venture builder that creates and funds biotech companies from academic research, backed by pharma investors including AstraZeneca and GSK. Its pharma-backed venture building model closely mirrors General Inception's collaboration with J&J Innovation.

TypeDirect peer
Description

BioGenerator is a St. Louis-based biotech venture studio that creates and funds life sciences companies from academic research. Its model of company creation with operational support directly parallels General Inception's Igniter approach, though it operates regionally rather than globally.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment9 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

General Inception

Venture Studio / Biotech Incubation Servicesgeneralinception.com

General Inception is a deep tech venture studio that co-founds biotech companies with scientific founders, operating a portfolio of 13+ companies across engineered biology, life sciences tools, diagnostics, and therapeutics, enhanced by AI and quantum-mechanics drug discovery platforms.

What General Inception does

General Inception is a deep tech venture studio founded in 2020 and headquartered in Palo Alto, California, that operates as a business co-founder for science-based companies. The studio partners with technical and scientific founders across engineered biology, life science tools and diagnostics, and therapeutics, guiding ventures from idea through seed investment and beyond via an "Igniter" model that supplies legal, financial, business strategy, and operations support alongside access to talent, customers, and institutional capital. As of recent disclosures, the studio maintains a portfolio of more than 13 biotech companies and operates with a team of 11-50 employees plus more than 20 Executives-in-Residence, with regional teams in France, Belgium, the Netherlands, and the United Kingdom through the Igniter Europe program launched in April 2024.

The studio's technology stack is anchored by two AI- and computational-driven platforms acquired or allied over 2023-2024. Enable Medicine (acquired December 2024) provides the Enable Atlas, a multimodal biological dataset indexed across billions of cells and thousands of patient data sets, and applies generative AI to search disease maps for novel drug targets and indications. Pharmacelera, under a 2023 strategic alliance, contributes a quantum mechanics and AI drug discovery platform that has completed more than 100 projects with repeat business from three big pharma clients. The studio's broader portfolio includes Resolve M Therapeutics (pro-resolution immunology, created with Johnson & Johnson Innovation – JJDC), Ennovate Pharma (autoimmune and inflammatory therapeutics), SonoNeu (sonogenetics, with up to $41.3M in ARPA-H funding), Biocellis (bioluminescence diagnostics with Institut Pasteur), Surf Therapeutics (ultrasound neuromodulation), and Planet Smart (biodegradable superabsorbent polymers).

General Inception's revenue model combines portfolio company equity appreciation with services revenue. Fractional services including Transformation Services, Fractional Finance, and Lab Services (GIL'S) originated as internal portfolio support and have expanded to external clients, while investors back the studio directly; named backers include Genoa Ventures, Hughes Ventures, Northpond Ventures, OMX Ventures, Paladin Capital Group, and Vertical Venture Partners. Pricing is not publicly disclosed and the studio does not report standalone revenue figures, with returns materially tied to portfolio company outcomes rather than product sales.

General Inception firmographics

Firmographics
Name
General Inception
Legal name
General Inception
Website
https://generalinception.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
General Inception is a deep tech venture studio that co-founds biotech companies with scientific founders, operating a portfolio of 13+ companies across engineered biology, life sciences tools, diagnostics, and therapeutics, enhanced by AI and quantum-mechanics drug discovery platforms.
Ownership category
akta.pro rank

General Inception industry classification

Industry
Product category
Venture Studio / Biotech Incubation Services
NAICS
Portfolio Management and Investment Advice (523940), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (54169), Scientific Research and Development Services (5417)
SIC
Services-Management Consulting Services (8742), Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAH
Venture Studios / Company Builders

Keywords

  • Venture studio services
  • Biotech company creation
  • Deep tech incubation
  • Fractional executive services
  • AI drug discovery

Where General Inception is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices8 records

Markets served

General Inception business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Portfolio Company Returns: General Inception operates as a venture studio that creates and scales biotech companies. Revenue is generated through successful portfolio company exits and equity appreciation.
  2. Services Revenue: Fractional services including Transformation Services, Fractional Finance, and Lab Services are offered to portfolio companies and external clients. Services began as internal support but expanded to serve external customers.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

General Inception product offering

Product offering

Core offering

General Inception operates as a Deep Tech Venture Studio that co-founds science-based companies with extraordinary technical founders, providing business co-founding services that span talent sourcing, customer introductions, and funding access from idea through seed investment and beyond. Complementing venture creation, GI sells discrete professional services — Transformation Services (fractional executive leadership for turnarounds and growth), Fractional Finance (CFO-level finance and accounting support), and Lab Services / GIL'S (R&D operations across fibrosis, oncology, inflammation, and autoimmune disease) — to portfolio companies and external clients.

Product overview

General Inception is a Deep Tech Venture Studio that operates as a business co-founder, partnering with scientific founders to build biotech companies. Rather than a single product, GI offers a portfolio of venture-building services (Transformation Services, Fractional Finance, Lab Services/GIL'S, Program Development Manager) and the Igniter Europe initiative for European company formation. GI's ecosystem includes 13+ portfolio companies spanning engineered biology, life science tools & diagnostics, and therapeutics, with core AI capabilities through the Enable Medicine acquisition enabling AI-led generative biological search for drug discovery.

Differentiator

Problem solved

Functional benefit

Products and services

  • Transformation Services

Quantifiable outcome

  • Successfully created Ennovate Pharma with validated targets for autoimmune disease non-responders
  • +3 more outcomes

Companies that use General Inception

Customer profile

Segments3 records

Ideal customer profiles3 records

General Inception technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

General Inception partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Salk InstitutecoreStrategic or Co-development Partner · 7 April 2026Salk Institute scientist Sreekanth Chalasani leads an ARPA-H project with up to $41.3M funding. Collaborating institutions include Scripps Research, Duke University, MIT, UC San Diego, California Medical Innovations Institute, and SonoNeu (a General Inception spinout).
  • Johnson & Johnson Innovation – JJDCcoreStrategic or Co-development Partner · 22 January 2026Resolve M Therapeutics was created through a strategic collaboration between Johnson & Johnson Innovation – JJDC and General Inception, leveraging insights from Professor Nir Hacohen's lab at the Broad Institute.
  • Institut PasteurcoreStrategic or Co-development Partner · 18 June 2025Biocellis announced equity partnership with General Inception and strategic collaboration with Institut Pasteur to accelerate bioluminescence-based diagnostics development and expand commercial reach of LuLISA technology.
  • Enable MedicinecoreTechnology or Integration · 12 December 2024General Inception acquired Enable Medicine and announced an equity and strategic partnership. The partnership provides GI greater access to Enable's biological data platform while Enable benefits from GI's drug development expertise and biotech ecosystem. The two companies first collaborated in 2023 to establish Ennovate Pharma.
  • Professor James ZouminorStrategic or Co-development Partner · 12 December 2024AI pioneer in life sciences and medicine; member of Enable Medicine's Scientific Advisory Board. Provided commentary on the transformative potential of Enable's biological data indexing and interrogation technology.
  • Ennovate PharmacoreStrategic or Co-development Partner · 12 December 2024Joint venture between General Inception and Enable Medicine established in 2023. Develops precision therapeutics for autoimmune and inflammatory diseases by leveraging biological atlases to identify and understand patient non-response to standard-of-care treatments. After 18 months, addressing refractory and non-responder populations with several validated targets.
  • Broad InstitutecoreStrategic or Co-development Partner · 12 December 2024Research collaboration with Professor Nir Hacohen's lab at the Broad Institute provided foundational science for Resolve M Therapeutics' pro-resolution platform for inflammatory diseases.
  • PharmaceleracoreTechnology or Integration · 1 January 2023General Inception established 2023 strategic alliance with Pharmacelera, where Pharmacelera became GI's strategic partner for AI-based drug discovery. GI's Chief Scientific Officer sits on Pharmacelera's Board of Directors. Pharmacelera has contributed to strengthening IP for several GI portfolio companies.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

General Inception competitors and assessment

Company assessment

Direct peers

  • IndieBio: IndieBio is a biotech accelerator that funds and incubates early-stage science startups, with programs in both San Francisco and New York. It is comparable to General Inception's deep-tech focus and venture creation model, though structured more as an accelerator than a long-term builder.
  • Flagship Pioneering: Flagship Pioneering is the largest and most established biotech venture studio, originating companies like Moderna. It is the closest analog to General Inception's model of creating and incubating multiple biotech ventures from scientific founders, with comparable portfolio scale and pharma partnership intensity.
  • MBC Biolabs: MBC Biolabs operates shared lab facilities and incubator programs for biotech startups in the San Francisco Bay Area. It represents a comparable biotech venture creation model focused on early-stage company formation with shared infrastructure — directly analogous to GIL'S Lab Services offering within General Inception.
  • Petri: Petri is a biotech venture studio that partners with scientists to launch new companies. It shares General Inception's focus on company creation at the intersection of biology and technology, though Petri operates at smaller scale and earlier stage.
  • Apollo Therapeutics: Apollo Therapeutics is a venture builder that creates and funds biotech companies from academic research, backed by pharma investors including AstraZeneca and GSK. Its pharma-backed venture building model closely mirrors General Inception's collaboration with J&J Innovation.
  • BioGenerator: BioGenerator is a St. Louis-based biotech venture studio that creates and funds life sciences companies from academic research. Its model of company creation with operational support directly parallels General Inception's Igniter approach, though it operates regionally rather than globally.

Broad incumbents

  • Evotec: Evotec is a global drug discovery and development company with a venture-building arm (e.g., Evotec's BRIDGE initiative) that co-creates biotech companies. As a much larger public company with broader CRO offerings, Evotec is an incumbent comparable to General Inception's biotech venture building activities.
  • BridgeBio Pharma: BridgeBio operates multiple subsidiary biotechs targeting genetic diseases through a portfolio model. Its broader scope and public market status make it a comparable incumbent, with similar strategic use of subsidiary structures and a focus on advancing multiple programs in parallel.
  • Recursion Pharmaceuticals: Recursion is an AI-driven drug discovery company that combines proprietary data platforms with a portfolio approach to therapeutic development. Its use of generative AI and large biological datasets to accelerate drug discovery is comparable to General Inception's Enable Medicine platform strategy.
  • Roivant Sciences: Roivant builds and operates multiple biotech subsidiaries (Vants) across therapeutic areas, using a hub-and-spoke model similar to GI's portfolio structure. While publicly traded and much larger, Roivant's approach to creating focused subsidiaries from scientific platforms is highly comparable to General Inception's portfolio strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

General Inception social profiles

Digital presence

General Inception financial estimates

Financial estimate

Revenue estimate

Valuation estimate

General Inception leadership team

Management profile

Number of profiles

Profiles4 records

General Inception subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

General Inception funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

General Inception M&A and investment

M&A and investment

M&A1 record

Investments9 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about General Inception

What does General Inception do?

General Inception operates as a Deep Tech Venture Studio that co-founds science-based companies with extraordinary technical founders, providing business co-founding services that span talent sourcing, customer introductions, and funding access from idea through seed investment and beyond. Complementing venture creation, GI sells discrete professional services — Transformation Services (fractional executive leadership for turnarounds and growth), Fractional Finance (CFO-level finance and accounting support), and Lab Services / GIL'S (R&D operations across fibrosis, oncology, inflammation, and autoimmune disease) — to portfolio companies and external clients.

Is General Inception a public or private company?

General Inception is a private company. It is classified as venture growth investor backed and is currently operating.

When was General Inception founded?

General Inception was founded in 2020. It employs 11 to 50 people.

Where is General Inception based?

General Inception is headquartered in San Francisco, United States, in the North America region.

How does General Inception make money?

Two revenue lines are on record. Portfolio Company Returns are the primary driver. The others are services Revenue.

Who are General Inception's main competitors?

Direct peers on record are IndieBio, Flagship Pioneering, MBC Biolabs, Petri, Apollo Therapeutics and BioGenerator. Broad incumbents are Evotec, BridgeBio Pharma, Recursion Pharmaceuticals and Roivant Sciences.

Does General Inception have an API?

No public API is recorded for General Inception.

What industry is General Inception in?

General Inception's product category is Venture Studio / Biotech Incubation Services. Its primary akta.pro industry code is FSANAAAH, Venture Studios / Company Builders. Its NAICS code is 523940 and its SIC code is 8742.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
CB InsightsProducts, Competitors, Financials, Employees, Headquarters LocationsPharmacelera, a Barcelona-based deep tech company applying quantum mechanics and AI to drug discovery, closed a €6 million Series A funding round led by Heran Partners with participation from Clave Capital, Inveready, and Bio&Tech Smart Capital. The funding will enable the company to establish a permanent team in the United States and expand the capabilities of its QaiM drug discovery platform. This round follows a 2023 strategic alliance with Silicon Valley-based General Inception, where Pharmacelera became GI's strategic partner for AI-based drug discovery.Pulse 2.0Resolve M Therapeutics Exits Stealth With Pro-Resolution Drug Discovery Platform Targeting Chronic InflammationResolve M Therapeutics emerged from stealth with a platform targeting pro-resolution pathways in chronic inflammation, formed via a collaboration between Johnson & Johnson Innovation and General Inception. The platform leverages the MS1 myeloid cell state to restore immune balance without broadly suppressing immunity. The company plans to pursue in vivo and in vitro methods to advance candidates with translational biomarkers.PR NewswireResolve M Therapeutics exits from stealthResolve M Therapeutics announced its exit from stealth, emerging as a biotech focused on building the world's first comprehensive pro-resolution platform for treating inflammatory diseases. The company was created through a strategic collaboration between Johnson & Johnson Innovation – JJDC, Inc. and General Inception, leveraging insights from Professor Nir Hacohen's lab at the Broad Institute. The platform aims to harness pro-resolving myeloid cells to restore immune homeostasis without broadly suppressing the immune system.PrwebBiocellis and General Inception announce equity partnership and strategic collaboration with Institut Pasteur.Biocellis announced an equity partnership with General Inception and a strategic collaboration with Institut Pasteur to accelerate its point-of-care diagnostic platform. The LuLISA technology offers 10x–100x greater sensitivity than existing methods, and the partnership includes the acquisition of Synthelis.FinSMEsGeneral Inception Acquires Enable MedicineGeneral Inception acquired Enable Medicine, a biotech igniter, for an undisclosed amount. The deal gives General Inception access to Enable Medicine's AI-led biological data platform, while Enable Medicine gains access to General Inception's drug development expertise and biotech ecosystem.outsourcing-pharma.comGeneral Inception acquires Enable Medicine to harness AI in drug discoveryGeneral Inception acquired Enable Medicine to combine its drug development expertise with Enable's biological data atlas. The companies will partner with healthcare providers and data repositories to deploy AI for drug target discovery. They also launched a new company with Deep Science Ventures to develop treatments for fibrosis.BenzingaGeneral Inception acquires Enable Medicine and announces strategic partnership to accelerate drug discovery with AI-led generative biological searchGeneral Inception acquired Enable Medicine in an equity and strategic partnership, with the deal amount undisclosed. The partnership combines Enable's AI-led biological search platform with General Inception's drug development expertise. The companies are now seeking data partnerships with healthcare providers and repositories.PR NewswireGeneral Inception acquires Enable Medicine and announces strategic partnership to accelerate drug discovery with AI-led generative biological searchGeneral Inception acquired Enable Medicine in an equity and strategic partnership, with the deal amount undisclosed. The partnership combines Enable's AI-led biological search platform with General Inception's drug development expertise. The companies are now seeking data partnerships with healthcare providers and repositories.PR NewswirePrecision Oncology Innovator SimBioSys and General Inception Announce Strategic Partnership to Accelerate Cancer Drug DevelopmentSimBioSys, a precision oncology company, and General Inception, a venture studio with over 40 portfolio companies, announced a strategic partnership on April 3, 2024 to accelerate oncology drug development using SimBioSys's AI-powered PhenoScope platform. The platform analyzes tumor spatial biophysical characteristics from a virtual tumor bank of over 20,000 tumors to enable precision dosing, patient stratification, and biomarker identification, with the goal of reducing development timelines and costs while improving patient outcomes. Under the agreement, all new oncology drug incubations under General Inception will utilize PhenoScope's capabilities for more efficient target identification and clinical positioning.